Table 1 Baseline characteristics of evaluable patients in the per protocol population
n = 23 evaluable patients | No. (%) | |
|---|---|---|
Age at inclusion, years | Median (range) | 60 (45–69) |
WHO performance status | WHO 0 WHO 1 | 12 (52) 11 (48) |
Histological subtype (assessed on metastatic lesion)a | ER+HER2– TNBC HER2+ | 18 (78) 5 (22) 0 (0) |
ILC subtype (assessed on metastatic lesion) | Classic Pleiomorphicb Alveolar | 17 (74) 4 (17) 2 (9) |
Germline BRCA1/BRCA2 mutations | gBRCA1 mutation No mutation Unknown | 1 (4) 4 (17) 18 (78) |
Visceral metastasis | 18 (78) | |
Liver metastasis | 12 (52) | |
No. of metastatic sites | 1–2 metastatic sites ≥3 metastatic sites | 12 (52) 11 (48) |
LDH | LDH ≤ ULN LDH ≤ 2× ULN | 15 (65) 8 (35) |
Previous chemotherapy exposure | Chemotherapy naive (Neo)adjuvant Palliative | 5 (22) 15 (65) 12 (52) |
Previous platinum treatment | ER+ TNBC | 0 (0) 2 (40% of TNBC) |
Previous exposure to CDK4/CDK6 inhibitors | ER+ TNBC | 17 (94% of ER+) 0 (0) |
Disease-free interval (DFI) | De novo M1 DFI ≤ 5 years DFI > 5 years | 5 (22) 12 (52) 6 (26) |
No. of cycles carboplatin | Median (range) | 9 (3–12) |
No. of cycles atezolizumab (anti-PD-L1) | Median (range) | 5 (1–16) |
